Natural Products and Long Noncoding RNAs: A Complex Regulatory Network in Pancreatic Cancer Progression and Treatment

Hanan Elimam1, Abdullah F Radwan2,3, Nourhan Elfar4,5

  • 1Department of Biochemistry, Faculty of Pharmacy, University of Sadat City, Sadat City, Egypt.

Insights

Long noncoding RNAs (lncRNAs) are crucial in pancreatic cancer (PC) development and resistance. Targeting lncRNAs offers new therapeutic strategies and diagnostic biomarkers for this lethal disease.

Area of Science:

  • Oncology
  • Molecular Biology
  • Genetics

Background:

  • Pancreatic cancer (PC) is a highly lethal malignancy with poor prognosis due to late diagnosis and therapeutic resistance.
  • Long noncoding RNAs (lncRNAs) are increasingly recognized as critical regulators in PC pathogenesis, affecting tumor initiation and progression.

Purpose of the Study:

  • To comprehensively review the biogenesis, molecular functions, and regulatory pathways of lncRNAs in pancreatic cancer.
  • To explore the role of lncRNAs in therapeutic resistance and their potential as diagnostic and prognostic biomarkers.

Main Methods:

  • Literature review focusing on lncRNA regulation via oncogenic pathways (PI3K/Akt, JAK/STAT, Wnt/β-catenin).
  • Detailed examination of lncRNA involvement in key cancer processes like EMT, invasion, proliferation, apoptosis evasion, angiogenesis, and metastasis.
  • Analysis of lncRNAs' role in resistance to chemotherapy, radiotherapy, and immunotherapy.

Main Results:

  • lncRNAs significantly influence PC progression by regulating epithelial-mesenchymal transition (EMT), invasion, proliferation, and metastasis.
  • lncRNAs are central mediators of resistance to various pancreatic cancer therapies.
  • Natural compounds show potential in modulating oncogenic pathways and improving therapeutic efficacy.

Conclusions:

  • lncRNAs play multifaceted roles in pancreatic cancer biology, impacting tumorigenesis and therapeutic outcomes.
  • lncRNAs hold significant potential as diagnostic and prognostic biomarkers for PC.
  • Targeting lncRNAs and leveraging natural compounds present promising avenues for novel pancreatic cancer therapies.

Related Concept Videos

lncRNA - Long Non-coding RNAs02:39

lncRNA - Long Non-coding RNAs

In humans, more than 80% of the genome gets transcribed. However, only around 2% of the genome codes for proteins. The remaining part produces non-coding RNAs which includes ribosomal RNAs, transfer RNAs, telomerase RNAs, and regulatory RNAs, among other types. A large number of regulatory non-coding RNAs have been classified into two groups depending upon their length – small non-coding RNAs, such as microRNA, which are less than 200 nucleotides in length, and long non-coding RNA (lncRNA)...
lncRNA - Long Non-coding RNAs02:39

lncRNA - Long Non-coding RNAs

In humans, more than 80% of the genome gets transcribed. However, only around 2% of the genome codes for proteins. The remaining part produces non-coding RNAs which includes ribosomal RNAs, transfer RNAs, telomerase RNAs, and regulatory RNAs, among other types. A large number of regulatory non-coding RNAs have been classified into two groups depending upon their length – small non-coding RNAs, such as microRNA, which are less than 200 nucleotides in length, and long non-coding RNA (lncRNA)...
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
MicroRNAs01:22

MicroRNAs

MicroRNA (miRNA) are short, regulatory RNA transcribed from introns (non-coding regions of a gene) or intergenic regions (stretches of DNA present between genes). Several processing steps are required to form biologically active, mature miRNA. The initial transcript, called primary miRNA (pri-mRNA), base-pairs with itself, forming a stem-loop structure. Within the nucleus, an endonuclease enzyme, called Drosha, shortens the stem-loop structure into hairpin-shaped pre-miRNA. After the pre-miRNA...
MicroRNAs01:22

MicroRNAs

MicroRNA (miRNA) are short, regulatory RNA transcribed from introns—non-coding regions of a gene—or intergenic regions—stretches of DNA present between genes. Several processing steps are required to form biologically active, mature miRNA. The initial transcript, called primary miRNA (pri-mRNA), base-pairs with itself forming a stem-loop structure. Within the nucleus, an endonuclease enzyme, called Drosha, shortens the stem-loop structure into hairpin-shaped pre-miRNA. After the pre-miRNA ends...